Gilead HIV Combo of Bictegravir & Lenacapavir Hits Phase 3 Goal
ReutersDec 15, 2025 3:37 PM
Dec 15 (Reuters) - Gilead Sciences Inc GILD.O:
GILEAD’S INVESTIGATIONAL SINGLE-TABLET REGIMEN OF BICTEGRAVIR AND LENACAPAVIR FOR HIV TREATMENT MEETS PRIMARY ENDPOINT IN PHASE 3 ARTISTRY-2 TRIAL
GILEAD - BIC/LEN EFFICACY STATISTICALLY NON-INFERIOR TO BIKTARVY
GILEAD - BIC/LEN WELL TOLERATED, NO SIGNIFICANT SAFETY CONCERNS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
U.S. November Nonfarm Payrolls: What Does the Rare "Weak Jobs, Strong Economy" Mix Mean for U.S. Equities?
TradingKey - The U.S. economy will likely maintain a divergent pattern of weak employment but robust growth in 2026...Therefore, the Fed is highly likely to scale up the magnitude of rate reductions in 2026.TradingKey
2 hours ago
US November Non-Farm Payrolls and CPI data both loom【The week ahead】
TradingKey - On the equities front, Micron Technology, Nike, Accenture, FedEx, and other companies will release earnings. Following significant volatility in AI-related stocks, Micron Technology's earnings performance is receiving particular market attention.TradingKey
18 hours ago
Netflix Stock Analysis: Why Netflix Stock Keeps Falling, and When Should Investors Buy Netflix Stock?
While the final terms for Netflix's acquisition of WBD remain uncertain in the short term, we view the recent decline, driven by market sentiment, as a significant long-term undervalued opportunity. The return to more realistic valuations enhances the investment appeal of Netflix stock.TradingKey
19 hours ago
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?TradingKey
Wed, Dec 10
Why Did Strategy's Stock Price Plummet? Can MSTR Reach $1,000?
MicroStrategy (MSTR) stock, despite pressures from Bitcoin volatility and its weak core business, represents the most leveraged investment in a Bitcoin bull market. The company's stock path to $1,000 largely depends on Bitcoin's market performance. Major institutions, including Standard Chartered anTradingKey
Thu, Dec 4
Tradingkey
